Clonal Hematopoiesis on Prognosis in Patients With Myocardial Infarction

Launched by YANG JING · Nov 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a condition called clonal hematopoiesis (CHIP) affects kidney health in patients who have had a heart attack, known as acute myocardial infarction (AMI). The research will look at 500 patients from October 2023 to July 2026 and is divided into three parts. The first part focuses on understanding how CHIP influences kidney problems in AMI patients. The second part examines how CHIP affects heart health in those with chronic kidney disease, and the third part looks at patients with end-stage renal disease. Researchers want to find out if CHIP is linked to serious outcomes like death or further heart attacks.

To participate, patients must have been diagnosed with a heart attack and received a specific procedure called percutaneous coronary intervention (PCI). People with severe heart or liver disease, those who are pregnant, or those with very poor kidney function cannot join the trial. Participants can expect to be monitored for various health outcomes, including heart-related issues and kidney function, over the study period. It's important to note that this is an observational study, meaning there won't be any treatments or changes to participants' health care; the focus is on gathering information to better understand the relationship between CHIP and health after a heart attack.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with AMI received PCI.
• Exclusion Criteria:
• • patients with severe heart disease, severe liver and kidney insufficiency, pregnancy, etc.